Breaking News

Symeres Acquires DGr Pharma

Expands its integrated early-stage drug development services and accelerates its IND-enabling capabilities for biopharma clients.

Author Image

By: Charlie Sternberg

Associate Editor

Symeres, a global contract research, development and manufacturing organization (CRDMO), has acquired DGr Pharma, a drug development-focused consultancy, to expand its integrated early-stage drug development services and accelerate IND-enabling capabilities for biopharma clients. The acquisition is supported by Keensight Capital, a private equity manager dedicated to pan-European Growth Buyout investments. Founded in 2018 and based in the Netherlands, DGr Pharma specializes in pre-clinical...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters